Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$18.70
-0.7%		$17.22
$8.01
▼
$24.27
$996.69M0.8872,402 shs596,212 shs
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$4.18
+6.4%		$21.00
$2.96
▼
$40.37
$227.59M0.545.74 million shs3.20 million shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$22.24
+2.5%		$19.67
$6.67
▼
$28.00
$1.07B1.49923,391 shs1.11 million shs
ODTX
Odyssey Therapeutics
$21.55
+3.2%		$17.78
$15.10
▼
$22.11
$1.00BN/A254,668 shs123,152 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-0.74%-3.56%-2.86%-13.31%+125.03%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
+6.36%-0.24%-81.19%-86.24%-45.99%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+2.49%+11.20%-0.94%-13.83%+184.04%
ODTX
Odyssey Therapeutics
+3.16%+16.99%+35.45%+2,154,999,900.00%+2,154,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$18.70
-0.7%		$17.22
$8.01
▼
$24.27
$996.69M0.8872,402 shs596,212 shs
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$4.18
+6.4%		$21.00
$2.96
▼
$40.37
$227.59M0.545.74 million shs3.20 million shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$22.24
+2.5%		$19.67
$6.67
▼
$28.00
$1.07B1.49923,391 shs1.11 million shs
ODTX
Odyssey Therapeutics
$21.55
+3.2%		$17.78
$15.10
▼
$22.11
$1.00BN/A254,668 shs123,152 shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-0.74%-3.56%-2.86%-13.31%+125.03%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
+6.36%-0.24%-81.19%-86.24%-45.99%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+2.49%+11.20%-0.94%-13.83%+184.04%
ODTX
Odyssey Therapeutics
+3.16%+16.99%+35.45%+2,154,999,900.00%+2,154,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
2.86
Moderate Buy$45.80144.92% Upside
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
1.91
Reduce$29.15597.37% Upside
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2.90
Moderate Buy$51.57131.89% Upside
ODTX
Odyssey Therapeutics
2.83
Moderate Buy$32.0048.49% Upside

Current Analyst Ratings Breakdown

Latest CAPR, ODTX, AVTX, and JBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
JonesTrading logo
JonesTrading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Neutral$2.00
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Neutral$3.50
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/28/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Alliance Global Partners logo
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$7.00
7/27/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/27/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
7/27/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$7.00
7/27/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$10.00
7/24/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$60K16,487.17N/AN/A$4.49 per share4.16
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$22.27M10.87N/AN/A$5.53 per share0.76
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/A$6.74 per shareN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$78.26M-$5.46N/AN/AN/AN/A-97.54%-72.42%N/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest CAPR, ODTX, AVTX, and JBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$0.58N/AN/AN/A$2.08 millionN/A
8/6/2026Q2 2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$0.5827-$0.83-$0.2473-$0.83N/AN/A
8/5/2026Q2 2026
ODTX
Odyssey Therapeutics
N/A-$1.74N/A-$1.74N/AN/A
6/17/2026Q1 2026
ODTX
Odyssey Therapeutics
-$1.31-$6.77-$5.46-$6.77N/AN/A
5/13/2026Q1 2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$1.00-$0.98+$0.02-$0.98$0.05 millionN/A
5/12/2026Q1 2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A
5/7/2026Q1 2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$0.52-$0.57-$0.05-$0.57N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/AN/AN/AN/AN/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/A
7.66
7.66
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/A
8.42
8.42
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
14.29
14.29
ODTX
Odyssey Therapeutics
N/A
8.33
8.33

Institutional Ownership

CompanyInstitutional Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
87.06%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
21.68%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
ODTX
Odyssey Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4.46%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
9.20%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
23.06%
ODTX
Odyssey Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4052.90 million50.54 millionNot Optionable
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
10157.91 million52.58 millionOptionable
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2049.36 million37.98 millionN/A
ODTX
Odyssey Therapeutics
N/A48.03 millionN/AN/A

Recent News About These Companies

Odyssey Therapeutics: Q2 Earnings Snapshot
August 6 at 7:12 AM  |  chron.comhttps://www.chron.com/business/article/odyssey-therapeutics-q2-earnings-snapshot-22376823.php
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
August 6 at 2:16 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evotec-and-odyssey-therapeutics-enter-ai-enabled-rd-collaboration-in-autoimmune-and-inflammatory-diseases-302844665.html
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338150/0/en/odyssey-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Brokerages
July 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30924225
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Given Consensus Rating of "Moderate Buy" by Brokerages
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/odyssey-therapeutics-inc-nasdaqodtx-given-consensus-rating-of-moderate-buy-by-brokerages-2026-07-22/
Odyssey Therapeutics Stock Price History
July 16, 2026  |  investing.comhttps://www.investing.com/equities/odyssey-therapeutics-inc-historical-data
Odyssey Therapeutics Inc ODTX
July 8, 2026  |  morningstar.comM
Odyssey Therapeutics Inc ODTX
July 8, 2026  |  morningstar.comM
Odyssey Therapeutics Inc Share Price (ODTX.US)
July 6, 2026  |  lse.co.ukhttps://www.lse.co.uk/SharePrice.html?shareprice=ODTX.US
Odyssey Therapeutics: Q1 Earnings Snapshot
June 18, 2026  |  chron.comhttps://www.chron.com/business/article/odyssey-therapeutics-q1-earnings-snapshot-22310114.php
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313811/0/en/odyssey-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
Odyssey Therapeutics Inc
May 26, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/odtx-odyssey-therapeutics-inc
A Boston biotech tried to go public last year but pulled back. Now it’s valued at nearly $1B
May 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/boston-biotech-tried-public-last-165524528.html
Insider Buying: Odyssey Therapeutics (NASDAQ:ODTX) Major Shareholder Buys 1,388,889 Shares of Stock
May 14, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-odtx-insider-buying-and-selling-2026-05-14/
Insider Buying: Odyssey Therapeutics (NASDAQ:ODTX) Director Buys $19,999,998.00 in Stock
May 13, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-odtx-insider-buying-and-selling-2026-05-13/
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
May 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/healthcare-ipos-raise-4-7-123114761.html
Insider Buying: Odyssey Therapeutics (NASDAQ:ODTX) CFO Acquires 1,000 Shares of Stock
May 12, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-odtx-insider-buying-and-selling-2026-05-12/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalo Therapeutics stock logo

Avalo Therapeutics NASDAQ:AVTX

$18.70 -0.14 (-0.74%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$18.51 -0.19 (-0.99%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Capricor Therapeutics stock logo

Capricor Therapeutics NASDAQ:CAPR

$4.18 +0.25 (+6.36%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$4.24 +0.06 (+1.48%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Jade Biosciences stock logo

Jade Biosciences NASDAQ:JBIO

$22.24 +0.54 (+2.49%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$22.26 +0.03 (+0.11%)
As of 08/6/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Odyssey Therapeutics NASDAQ:ODTX

$21.55 +0.66 (+3.16%)
As of 08/6/2026 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas